Citations

Clear

9383 citation(s) found for "Thomas, PS".

Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia
Maurer, Matthew J. , Allmer, Cristine, Rabe, Kari G. , Weiner, George J. , Call, Timothy G. , Link, Brian K. , Hanson, Curtis A. , Cerhan, James R. , Shanafelt, Tait D. , Drake, Matthew T. , Slager, Susan L. , Zent, Clive S. , Kay, Neil E. , Witzig, Thomas E. , Chaffee, Kari G. , Maurer, Matthew , Cerhan, James R , Link, Brian K , Weiner, George

Mayo Clinic

Blood | November 3, 2010 | Volume: 117 | Issue: 5 | Pages: 1492-1498

10.1182/blood-2010-07-295683 | PMID 21048153 Get It

Abstract Vitamin D insufficiency is common globally and low levels are linked to higher cancer incidence. Although vitamin D insufficiency is related to inferior prognosis in some cancers, no data exist for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). We evaluated the relationship of 25(OH)D serum levels with time-to-treatment (TTT) and overall survival (OS) in newly diagnosed CLL patients participating in a prospective cohort study (discovery cohort) and a separate cohort of previously untreated patients participating in an observational study (confirmation cohort). Of 390 CLL patients in the discovery cohort, 119 (30.5%) were 25(OH)D insufficient. After a median follow-up of 3 years, TTT (hazard ratio[HR] = 1.66; P = .005) and OS (HR = 2.39; P = .01) were shorter for 25(OH)D-insufficient patients. In the validation cohort, 61 of 153 patients (39.9%) were 25(OH)D insufficient. After a median follow-up of 9.9 years, TTT (HR = 1.59; P = .05) and OS (HR 1.63; P = .06) were again shorter for 25(OH)D-insufficient patients. On pooled multivariable analysis of patients in both cohorts adjusting for age, sex, Rai stage, CD38 status, ZAP-70 status, immunoglobulin heavy chain variable (IGHV) gene mutation status, CD49d status, and cytogenetic abnormalities assessed by interphase fluorescent in situ hybridization testing, 25(OH)D insufficiency remained an independent predictor of TTT (HR = 1.47; P = .008), although the association with OS was not significant (HR = 1.47; P = .07). Vitamin D insufficiency is associated with inferior TTT and OS in CLL patients. Whether normalizing vitamin D levels in deficient CLL patients would improve outcome merits clinical testing.
A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling
Hildebrand, Joanne M. , Luo, Zhenghua , Price-Troska, Tammy, Ziesmer, Steven C., Lin, Wai, Hostager, Bruce S. , Ansell, Stephen M. , Cerhan, James R. , Bishop, Gail A. , Novak, Anne J. , Manske, Michelle K. , Slager, Susan L. , Witzig, Thomas E. , Cerhan, James R

Mayo Clinic

Journal of Experimental Medicine | November 2, 2010 | Volume: 207 | Issue: 12 | Pages: 2569-2579

10.1084/jem.20100857 | PMID 21041452 Get It

The cytokine B cell activating factor (BAFF) and its receptor, BAFF receptor (BAFF-R), modulate signaling cascades critical for B cell development and survival. We identified a novel mutation in TNFRSF13C, the gene encoding human BAFF-R, that is present in both tumor and germline tissue from a subset of patients with non-Hodgkin lymphoma. This mutation encodes a His159Tyr substitution in the cytoplasmic tail of BAFF-R adjacent to the TRAF3 binding motif. Signaling through this mutant BAFF-R results in increased NF-κB1 and NF-κB2 activity and increased immunoglobulin production compared with the wild-type (WT) BAFF-R. This correlates with increased TRAF2, TRAF3, and TRAF6 recruitment to His159Tyr BAFF-R. In addition, we document a requirement for TRAF6 in WT BAFF-R signaling. Together, these data identify a novel lymphoma-associated mutation in human BAFF-R that results in NF-κB activation and reveals TRAF6 as a necessary component of normal BAFF-R signaling.
Summary of the Recommendations on Sexual Dysfunctions in Men
Montorsi, Francesco , Adaikan, Ganesan, Becher, Edgardo, Khoury, Saad, Lue, Tom F. , Sharlip, Ira D., Althof, Stanley E., Andersson, Karl-Eric, Brock, Gerald, Broderick, Gregory A. , Buvat, Jacques, Dean, John, Donatucci, Craig F., Eardley, Ian , Fugl-Meyer, Kerstin , Hackett, Geoff , Hatzichristou, Dimitris, Hellstrom, Wayne J.G. , Incrocci, Luca , Jackson, Graham, Levine, Laurence A. , Lewis, Ronald W., McCabe, Marita P. , McMahon, Chris G., Montague, Drogo K. , Montorsi, Piero, Mulhall, John P. , Pfaus, Jim, Porst, Hartmut, Ralph, David , Rosen, Raymond C., Sadeghi‐Nejad, Hossein , Shabsigh, Ridwan, Vardi, Yoram, Wallen, Kim , Wasserman, Marlene, Larcher, Alessandro , Giuliano, François , Burnett, Arthur L. “Bud” , Buvat, Jacques, Goldstein, Irwin , Kadıoğlu, Ateş , Maggi, Mario , Rowland, David L. , Stief, Christian G.

Mayo Clinic

The Journal of Sexual Medicine | October 29, 2010 | Volume: 7 | Issue: 11 | Pages: 3572-3588

10.1111/j.1743-6109.2010.02062.x | PMID 21040491 Get It

ABSTRACT Introduction Sexual health is an integral part of overall health. Sexual dysfunction can have a major impact on quality of life and psychosocial and emotional well-being. Aim To provide evidence-based, expert-opinion consensus guidelines for clinical management of sexual dysfunction in men. Methods An international consultation collaborating with major urologic and sexual medicine societies convened in Paris, July 2009. More than 190 multidisciplinary experts from 33 countries were assembled into 25 consultation committees. Committee members established scope and objectives for each chapter. Following an exhaustive review of available data and publications, committees developed evidence-based guidelines in each area. Main Outcome Measures New algorithms and guidelines for assessment and treatment of sexual dysfunctions were developed based on work of previous consultations and evidence from scientific literature published from 2003 to 2009. The Oxford system of evidence-based review was systematically applied. Expert opinion was based on systematic grading of medical literature, and cultural and ethical considerations. Results Algorithms, recommendations, and guidelines for sexual dysfunction in men are presented. These guidelines were developed in an evidence-based, patient-centered, multidisciplinary manner. It was felt that all sexual dysfunctions should be evaluated and managed following a uniform strategy, thus the International Consultation of Sexual Medicine (ICSM-5) developed a stepwise diagnostic and treatment algorithm for sexual dysfunction. The main goal of ICSM-5 is to unmask the underlying etiology and/or indicate appropriate treatment options according to men’s and women’s individual needs (patient-centered medicine) using the best available data from population-based research (evidence-based medicine). Specific evaluation, treatment guidelines, and algorithms were developed for every sexual dysfunction in men, including erectile dysfunction; disorders of libido, orgasm, and ejaculation; Peyronie’s disease; and priapism. Conclusions Sexual dysfunction in men represents a group of common medical conditions that need to be managed from a multidisciplinary perspective.
Living Human Dynamic Response to —G x Impact Acceleration II—Accelerations Measured on the Head and Neck
Ewing, C. L., Thomas, Daniel , Patrick, L. M., Beeler, George W., Smith, M

Mayo Clinic

SAE Technical Paper Series | October 25, 2010 | Volume: 1 | Issue: No issue available | Pages: No page available

10.4271/690817 Get It

<div class="htmlview paragraph">A methodical investigation and measurement of human dynamic response to impact acceleration is being conducted as a Joint Army-Navy-Wayne State University investigation. Details of the experimental design were presented at the Twelfth Stapp Car Crash Conference in October 1968.</div> <div class="htmlview paragraph">Linear accelerations are being measured on the top of the head, at the mouth, and at the base of the neck. Angular velocity is also being measured at the base of the neck and at the mouth. A redundant photographic system is being used for validation. All data are collected in computer compatible format and data processing is by digital computer. Selected data in a stage of interim analysis on 18 representative human runs of the 236 human runs completed to date are presented.</div> <div class="htmlview paragraph">Review of the data indicates that peak accelerations measured at the mouth are higher than previous estimates. The time relationship of the peak resultant mouth accelerations to the peak sled acceleration for this particular accelerator and restraint system is described. The maximum peak resultant mouth acceleration was 47.8 g and the peak mouth angular velocity on another run exceeded 30 rad/sec, on nominal 10 g, 250 g/sec runs. Clinical evaluation of the subjects before and after the runs disclosed no evidence of unconsciousness or neurological deficit attributable to the acceleration.</div> <div class="htmlview paragraph">Representative plots of the human dynamic response are presented, discussed, and compared. A first-order linear regression analysis for the peak mouth resultant acceleration and the peak mouth angular velocity obtainable from the peak sled acceleration is presented.</div>
Impact of Overall Treatment Time on Survival and Local Control in Patients With Anal Cancer: A Pooled Data Analysis of Radiation Therapy Oncology Group Trials 87-04 and 98-11
Ben‐Josef, Edgar , Moughan, Jennifer, Flam, Marshall S., Gunderson, Leonard L., Pollock, Jondavid , Myerson, Robert J., Anne, Rani, Willett, Christopher G. , Ajani, Jaffer A. , Rosenthal, Seth A.

Mayo Clinic

Journal of Clinical Oncology | October 19, 2010 | Volume: 28 | Issue: 34 | Pages: 5061-5066

10.1200/jco.2010.29.1351 | PMID 20956625 Get It

PurposeTo determine whether increased duration of radiation therapy (RT) and overall treatment (RX) time has a detrimental effect in anal cancer.Patients and MethodsData from Radiation Therapy Oncology Group (RTOG) 87-04 and RTOG 98-11 trials were combined to form three treatment groups: RT/fluorouracil (FU)/mitomycin (n = 472), RT/FU/cisplatin (n = 320), and RT/FU (n = 145). Cox proportional hazards models were used with the following variables: RT duration, RT intensity, RX duration, treatment group, age, sex, Karnofsky performance score (KPS), T stage, N stage, and RT dose.ResultsIn the univariate analysis, there was a significant association between RX duration and colostomy failure (CF; hazard ratio [HR] = 1.51; 95% CI, 1.07 to 2.14; P = .02), local failure (HR = 1.52; 95% CI, 1.14 to 2.03; P = .005), locoregional failure (HR = 1.51; 95% CI, 1.15 to 1.98; P = .003), and time to failure (HR = 1.40; 95% CI, 1.10 to 1.79; P = .007). The significance of RX duration was maintained after adjusting for treatment group. In multivariate modeling there was a trend toward an association between RX duration and CF (HR = 1.57; 95% CI, 0.98 to 2.50; P = .06) and a statistically significant association with local failure (HR = 1.96; 95% CI, 1.34 to 2.87; P = .0006). Age, sex, KPS, T stage, N stage, and RT dose, but not RT duration, RT intensity, or RX duration, were found to be statistically significant predictors of OS and colostomy-free survival.ConclusionTotal treatment time, but not duration of radiation therapy, seems to have a detrimental effect on local failure and colostomy rate in anal cancer. Induction chemotherapy may contribute to local failure by increasing total treatment time.
Influence of Cardiomegaly on Disordered Breathing During Exercise in Chronic Heart Failure
Olson, Thomas P. , Johnson, Bruce D.

Mayo Clinic

European Journal of Heart Failure | October 18, 2010 | Volume: 13 | Issue: 3 | Pages: 311-318

10.1093/eurjhf/hfq177 | PMID 20952768 Get It

Abstract Aims Heart failure (HF) patients breathe with a rapid shallow pattern during exercise. This study examined the relationship between cardiac size and tachypnoeic breathing in HF patients during exercise. Methods and results Thirty-seven HF patients [age = 55 ± 13 years, ejection fraction (EF) = 27 ± 10%, New York Heart Association (NYHA) class = 2.3 ± 1.2] and 42 controls (CTL) (age = 56 ± 14 years, EF = 63 ± 8%) were recruited. Participants underwent maximal exercise testing, pulmonary function testing, and chest radiography for calculation of total thoracic cavity volume (TTCV), diaphragm, heart, and lung volumes. Heart failure patients were divided into two groups: Group A = cardiac volume &lt; median (n = 18) and Group B = cardiac volume ≥ median of the HF patients (n = 19). There was no difference between groups for TTCV (CTL = 8203 ± 1489 vs. Group A = 8694 ± 1249 vs. Group B = 8195 ± 1823 cm3). Cardiac volume was different between groups for both absolute (CTL = 630 ± 181 vs. Group A = 894 ± 186 vs. Group B = 1401 ± 382 cm3, P&lt; 0.001 for all comparisons) and %TTCV (CTL = 8 ± 2 vs. Group A = 10 ± 1 vs. Group A = 18 ± 5%, P&lt; 0.001 for all comparisons). Similarly, total lung volume as a %TTCV was significantly different among the groups (CTL = 70 ± 4 vs. Group A = 65 ± 5 vs. Group A = 58 ± 7%, P&lt; 0.01 for all comparisons). In HF patients, there was a trend (P = 0.10) towards an independent association between cardiac size and tidal volume (VT) at 75% of VO2 peak whereas this relationship was statistically significant at VO2 peak (P = 0.02) as patients with larger cardiac size had reduced VT. Conclusion This study demonstrates the close relationship between cardiac size and breathing pattern during exercise in HF patients. These results suggest cardiac size may pose a significant constraint on the lungs during exercise and may contribute to tachypnoeic breathing.
PGC-1 α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease
Liao, Zhixiang , Locascio, Joseph J. , Lesniak, Kristen A., Roderick, Sarah S., Watt, Marla L., Eklund, Aron C. , Zhang‐James, Yanli , Kim, Peter D., Hauser, Michael A. , Grünblatt, Edna , Moran, Linda, Mandel, Silvia, Riederer, Peter , Miller, Renee M. , Federoff, Howard J. , Papapetropoulos, Spyridon , Youdim, Moussa B. H. , Cantuti‐Castelvetri, Ippolita, Young, Anne B., Vance, Jeffery M. , Hedreen, John C. , Beach, Thomas G. , Graeber, Manuel B., Middleton, Frank A. , Rochet, Jean‐Christophe , Scherzer, Clemens R. , Papapetropoulos, Spyros , Zheng, Bin , Wüllner, Ullrich , Davis, Richard L. , Adler, Charles H.

Mayo Clinic

Science Translational Medicine | October 6, 2010 | Volume: 2 | Issue: 52 | Pages: No page available

10.1126/scitranslmed.3001059 | PMID 20926834 Get It

Abnormal expression of genes for energy regulation in Parkinson’s disease patients identifies a master regulator as a possible therapeutic target for early intervention.
Improvement in Left Ventricular Systolic and Diastolic Performance During Ranolazine Treatment in Patients With Stable Angina
Figueredo, Vincent M. , Pressman, Gregg S. , Romero‐Corral, Abel, Murdock, Elmer, Holderbach, Pat, Morris, Danielle

Mayo Clinic

Journal of Cardiovascular Pharmacology and Therapeutics | October 6, 2010 | Volume: 16 | Issue: 2 | Pages: 168-172

10.1177/1074248410382105 | PMID 20924097 Get It

Purpose: Ranolazine is a novel antianginal medication that acts by ameliorating disturbed sodium and calcium homeostasis. By preventing myocyte sodium and calcium overload, ranolazine also have potential beneficial effects on myocardial function. Experimental models support this concept, as do 2 small studies in human participants receiving ranolazine intravenously. We evaluated changes in parameters of left ventricular function in stable angina patients treated with oral ranolazine. Methods: Twenty-two participants were enrolled with Doppler echocardiography performed at baseline and a mean of 2 months after initiation of treatment. Results: Global left ventricular function, as assessed by the myocardial performance index, was significantly improved on drug therapy (P < .0001). This was due to improvement in both diastolic and systolic parameters. Of 21 patients, 17 reported less angina and 8 patients reported an increase in activity level. Conclusions: We report improved parameters of left ventricular function in response to ranolazine as used in the clinical setting.
The Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST)
Mantese, Vito A., Timaran, Carlos H. , Chiu, David, Begg, Richard J., Brott, Thomas G.

Mayo Clinic

Stroke | September 27, 2010 | Volume: 41 | Issue: 10_suppl_1 | Pages: No page available

10.1161/strokeaha.110.595330 | PMID 20876500 Get It

Background and Purpose— Carotid artery stenosis causes up to 10% of all ischemic strokes. Carotid endarterectomy (CEA) was introduced as a treatment to prevent stroke in the early 1950s. Carotid stenting (CAS) was introduced as a treatment to prevent stroke in 1994. Methods— The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) is a randomized trial with blinded end point adjudication. Symptomatic and asymptomatic patients were randomized to CAS or CEA. The primary end point was the composite of any stroke, myocardial infarction, or death during the periprocedural period and ipsilateral stroke thereafter, up to 4 years. Results— There was no significant difference in the rates of the primary end point between CAS and CEA (7.2% versus 6.8%; hazard ratio, 1.11; 95% CI, 0.81 to 1.51; P =0.51). Symptomatic status and sex did not modify the treatment effect, but an interaction with age and treatment was detected ( P =0.02). Outcomes were slightly better after CAS for patients aged <70 years and better after CEA for patients aged >70 years. The periprocedural end point did not differ for CAS and CEA, but there were differences in the components, CAS versus CEA (stroke 4.1% versus 2.3%, P =0.012; and myocardial infarction 1.1% versus 2.3%, P =0.032). Conclusions— In CREST, CAS and CEA had similar short- and longer-term outcomes. During the periprocedural period, there was higher risk of stroke with CAS and higher risk of myocardial infarction with CEA. Clinical Trial Registration— www.clinicaltrials.gov. Unique identifier: NCT00004732.
Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study
Saper, Joel R., Silberstein, Stephen D., McCarville, Sally, Sun, Mark Y., Goadsby, Peter J. , Dodick, David W. , Goadsby, Peter J

Mayo Clinic

Cephalalgia | September 23, 2010 | Volume: 31 | Issue: 3 | Pages: 271-285

10.1177/0333102410381142 | PMID 20861241 Get It

Background: Medically intractable chronic migraine (CM) is a disabling illness characterized by headache ≥15 days per month. Methods: A multicenter, randomized, blinded, controlled feasibility study was conducted to obtain preliminary safety and efficacy data on occipital nerve stimulation (ONS) in CM. Eligible subjects received an occipital nerve block, and responders were randomized to adjustable stimulation (AS), preset stimulation (PS) or medical management (MM) groups. Results: Seventy-five of 110 subjects were assigned to a treatment group; complete diary data were available for 66. A responder was defined as a subject who achieved a 50% or greater reduction in number of headache days per month or a three-point or greater reduction in average overall pain intensity compared with baseline. Three-month responder rates were 39% for AS, 6% for PS and 0% for MM. No unanticipated adverse device events occurred. Lead migration occurred in 12 of 51 (24%) subjects. Conclusion: The results of this feasibility study offer promise and should prompt further controlled studies of ONS in CM.